Skip to content
My WebMD Sign In, Sign Up

Multiple Sclerosis Health Center

Font Size

Cancer Drug Rituxan Cuts MS Flare-ups

Studies Show Multiple Sclerosis Patients Taking Rituxan Have Fewer Brain Lesions

Fewer Flare-ups in People on Rituxan

Both of the new studies involved people with the relapsing-remitting form of MS. In the first study, 69 people were given two one-hour infusions of Rituxan two weeks apart and 35 were given a placebo.

Over the next six months, 58% fewer people taking the drug had their symptoms flare up than those taking placebo: 14.5% of those on Rituxan experienced at least one relapse compared with 34.3% of those receiving a placebo.

Also, those on Rituxan had 91% fewer brain lesions seen on MRIs than those on placebo, Hauser says.

The second study, designed to look at the safety of the drug, showed "no unexpected problems," says researcher Amit Bar-Or, MD, of the Montreal Neurological Institute at McGill University in Montreal.

Twenty-six of 28 people were able to complete the 48-week study, in which they received two infusions of Rituxan two weeks apart and then another course six months later.

Most side effects were limited to mild to moderate reactions to the drug infusion, such as headaches and chills, Bar-Or tells WebMD. The two people who dropped out had infusion-related headaches.

Both studies were supported by Genentech Inc., and Biogen Idec., the companies that market the drug for certain types of lymphoma and for a moderate to severe form of rheumatoid arthritis in the U.S.

Safety a Concern

Gary Birnbaum, MD, director of the Multiple Sclerosis Treatment and Research Center in Golden Valley, Minn., says a big worry is a rare but rapidly fatal viral infection known as progressive multifocal leukoencephalopathy, or PML.

And while people on Rituxan appear to have fewer MS flare-ups, "we still don't know if it will actually stop disease progression," Birnbaum tells WebMD.

"These are important observations," Birnbaum says. "But we need longer trials to assess safety and effectiveness."

Immediate Drug Therapy Better Than Waiting

In a third study presented at the meeting, researchers reported that people who immediately start taking Betaseronat the first signs of MS are 41% less likely to have another attack over the next three years than those who delay treatment until they are diagnosed, as is currently done.

Betaseron is a brand of the interferon beta medications that are already used to treat people with relapsing-remitting MS. Other brands of interferon beta, which may reduce the frequency of relapses and delay disability, are Avonex and Rebif.

"I was one of those skeptics who told patients [who had one attack] we could wait," says researcher Mark S. Freedman, MD, director of the Multiple Sclerosis Unit at the University of Ottawa.

"But it turns out there is an 80% chance a person who has one attack will meet the criteria for MS by two years," he tells WebMD. "Immediate treatment can prevent or delay the chance of progression."

Freedman says it's possible that immediate treatment with the other interferon beta medications would provide the same benefit. "But it hasn't been shown."

1|2

Today on WebMD

brain and teriflunomide molecule
ARTICLE
neural fiber
ARTICLE
 
white blood cells
VIDEO
linguini with asparagus and mushrooms
ARTICLE
 
brain scan
ARTICLE
worried woman
ARTICLE
 
person writin in a notebook
ARTICLE
couple embracing
ARTICLE
 
man with cane
SLIDESHOW
skull and neck xray
ARTICLE
 
Stressed man
ARTICLE
doctor feeling patients neck
ASSESSMENT